Where do you study? ●●●●●●e 5 ●●●●●● R●●●●●●'s final offer was $13 in cash per share as well as a "●●●●●●gent value right" that could have added a ●●●●●●r $2.50 per share if Elan's ●●●●●●uster ●●●●●●le ●●●●●●sis drug T●●●●●● hit ●●●●●●n sales ●●●●●●ones.
